U0126 (20 μM, ERK1/2 MAPK inhibitor) with or without fraxetin (20 μM for Huh7 and 50 μM for Hep3B) decreased the proliferation of HCC cells by >5-fold (Figure 8). Here, MAPK3 is linked to hepatocellular carcinoma.